Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Gold Prices Slide as Iran Conflict Fuels Fed Rate Hike Bets
Asian Currencies Mixed as Yen Nears 160, Oil Surges
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies
Bessent Urges Japan on Fiscal Discipline, BOJ Rate Hikes
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
China Manufacturing PMI Contracts Again as Recovery Remains Fragile
OpenAI Rejects Apple Trade Secret Theft Claims
India Manufacturing Growth Slows to Five-Year Low in August
Amazon Secures 200 MW Wind Power Deals in Sweden
OpenAI Nears Astra AI Model Launch With Safety Focus
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips
Dollar Holds Near Two-Week High as Fed Rate Hike Bets Rise
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations
South Korea Inflation Rises to 3.1% in August 



